Reuters -- U.S. drug reviewers will ask an advisory panel if they should wait for more data before deciding whether to approve a proposed ovarian cancer drug from Johnson & Johnson (JNJ.N) and Spanish company Zeltia (ZEL.MC), documents released on Monday said.
